- Home
- VRAX vs CYCN Comparison
VRAX vs CYCN Comparison
Compare VRAX & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | CYCN |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 5.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRAX | CYCN |
|---|---|---|
| Price | $0.24 | $1.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 199.5K | 134.1K |
| Earning Date | 01-01-0001 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,986.00 | ★ $2,855,000.00 |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1371.65 |
| 52 Week Low | $0.22 | $1.03 |
| 52 Week High | $2.10 | $4.31 |
Technical Indicators
Market Signals| Indicator | VRAX | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 30.83 | 45.23 |
| Support Level | $0.22 | $1.03 |
| Resistance Level | $0.26 | $1.52 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 13.00 | 36.69 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.